Dr. Lewis used the AI-powered device on a patient with severe lumbar stenosis.
Dr. Jonathan Lewin is the first surgeon in the state of New Jersey to use the PathKeeper Surgical Spinal Navigation System on a live patient.1 According to a press release, the Director of the Center for Musculoskeletal Disorders used the device on a procedure for an 80-year-old patient with severe lumbar stenosis.
The PathKeeper combines infrared laster-optical 3D cameras with AI-based technology to provide surgeons with sub-millimetric accuracy. The technology is able to provide real-time imaging and navigation capabilities. The device was developed by Israeli medical technology PathKeeper Surgical.
In a press release, Dr. Lewin said, “I am thrilled to have the opportunity to pioneer the use of PathKeeper in New Jersey. This innovative technology opens new doors for precision and safety in spinal procedures, without radiation, ultimately enhancing patient outcomes and quality of life."
In the same press release, PathKeeper Surgical CEO and founder Erez Lampert said, “We are happy to work with Dr. Lewin and excited for the continued adoption of PathKeeper. We have built a next generation platform that should help surgeons improve clinical outcomes for patients and provide significant value to health systems."
In January of this year, PathKeeper announced that the device had been used by doctors in Connecticut.2 Dr. Shirvinda Wijesekera, MD, and Dr. Glenn Russo, MD, used the PathKeeper System during a spinal fusion procedure at Midstate Medical Center in Meriden, CT.
In a press release issued at the time, Wijesekera, said, "The PathKeeper system has an easy learning curve, impressive accuracy, and I believe there is significant value in optical navigation to reduce time and radiation in the operating room. I am excited to see how PathKeeper continues to develop their platform, especially for spinal deformity correction."
In the same press release, PathKeeper’s chief commercial officer Ryan LeBlanc said, “We believe there are several unique value propositions that will be significant for the future of surgical navigation and robotics. Critical areas of improvement are a more efficient surgical workflow, elimination of radiation exposure during the surgical procedure, and a more economical price point so smaller hospitals, ambulatory-surgical centers, and emerging markets can incorporate this technology."
Aside from developing AI-powered surgical systems, PathKeeper is working on other ways to improve spinal surgical procedures. In March of this year, the company announced that it had entered into a know-how agreement with the Mayo Clinic to research ways to minimize radiation levels during pediatric spinal surgeries.3
At the time, Lampert said, “We are proud to collaborate with Mayo Clinic. Our focus on accuracy and radiation reduction underscores our commitment to advancing spine surgery, and providing surgeons with the information they need to make decisions with very high precision."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
2 Commerce Drive
Cranbury, NJ 08512